GLP-1 Receptors Agonists in Type 2 Diabetes
Mechanistic Insights and Evolving Treatment Options
Diabetes mellitus–related all‐cause and cardiovascular mortality in a national cohort of adults.
Raghavan S, et al. J Am Heart Assoc. 2019;8(4):e011295.
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus.
Zelniker TA, et al. Circulation. 2019;139(17):2022–2031.
Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD [European Foundation for the Study of Diabetes] Study Group.
Schnell O, et al. Cardiovasc Diabetol. 2019;18(1):30.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial.
Gerstein HC, et al. Lancet. 2019;394(10193):121-130.
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Husain M, et al. N Engl J Med. 2019; 381(9):841-851.
54-OR: oral semaglutide vs. empagliflozin added on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2.
Montanya E, et al. Diabetes. 2019;68(suppl 1):54-OR.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Pratley R, et al. Lancet. 2019;394(10192):39-50.
A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes
Romera I, et al. Diabetes Ther. 2019;10(1):5-19.
Guidelines
Standards of medical care in diabetes—2019.
American Diabetes Association. Diabetes Care. 2019;42(suppl 1):S1-S193.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
Garber AJ, et al. Endocr Pract. 2019;25(1):69-100.
Patient Advocacy Organizations and Resources
American Diabetes Association (ADA)
The American Diabetes Association is the nation's leading nonprofit charity fighting against diabetes and its deadly consequences.
American Association of Diabetes Educators (AADE)
The AADE is an interdisciplinary professional membership organization dedicated to improving prediabetes, diabetes, and cardiometabolic care through innovative education, management, and support.
Centers for Disease Control and Prevention (CDC)
The CDC increases the health security of our nation by fighting disease and supporting efforts of communities and citizens to do the same.
National Diabetes Education Program (NDEP)
The NDEP works collaboratively with its partner organizations to improve the treatment and outcomes for people with diabetes as well as promoting its prevention and early diagnosis.
GLP-1 Receptors Agonists in Type 2 Diabetes
Mechanistic Insights and Evolving Treatment Options
| Faculty: | Kathleen Dungan, MD, MPH; Javier Morales, MD, FACP, FACE |
| Release: | 10/21/2019 |
| Expiration: | 10/21/2020 |
